248 related articles for article (PubMed ID: 12680223)
1. Induction mechanism of apoptosis by troglitazone through peroxisome proliferator-activated receptor-gamma in gastric carcinoma cells.
Yoshida K; Tanabe K; Fujii D; Oue N; Yasui W; Toge T
Anticancer Res; 2003; 23(1A):267-73. PubMed ID: 12680223
[TBL] [Abstract][Full Text] [Related]
2. Activation of peroxisome proliferator-activated receptor gamma by troglitazone inhibits cell growth through the increase of p27KiP1 in human. Pancreatic carcinoma cells.
Motomura W; Okumura T; Takahashi N; Obara T; Kohgo Y
Cancer Res; 2000 Oct; 60(19):5558-64. PubMed ID: 11034103
[TBL] [Abstract][Full Text] [Related]
3. The ligands of peroxisome proliferator-activated receptor (PPAR) gamma inhibit growth of human esophageal carcinoma cells through induction of apoptosis and cell cycle arrest.
Fujii D; Yoshida K; Tanabe K; Hihara J; Toge T
Anticancer Res; 2004; 24(3a):1409-16. PubMed ID: 15274302
[TBL] [Abstract][Full Text] [Related]
4. Peroxisome proliferator-activated receptor gamma ligand troglitazone induces cell cycle arrest and apoptosis of hepatocellular carcinoma cell lines.
Yoshizawa K; Cioca DP; Kawa S; Tanaka E; Kiyosawa K
Cancer; 2002 Nov; 95(10):2243-51. PubMed ID: 12412180
[TBL] [Abstract][Full Text] [Related]
5. Ligand for peroxisome proliferator-activated receptor gamma (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo.
Kubota T; Koshizuka K; Williamson EA; Asou H; Said JW; Holden S; Miyoshi I; Koeffler HP
Cancer Res; 1998 Aug; 58(15):3344-52. PubMed ID: 9699665
[TBL] [Abstract][Full Text] [Related]
6. Peroxisome proliferator-activated receptor ligands affect growth-related gene expression in human leukemic cells.
Laurora S; Pizzimenti S; Briatore F; Fraioli A; Maggio M; Reffo P; Ferretti C; Dianzani MU; Barrera G
J Pharmacol Exp Ther; 2003 Jun; 305(3):932-42. PubMed ID: 12649303
[TBL] [Abstract][Full Text] [Related]
7. Peroxisome proliferator-activated receptor gamma ligands induce cell cycle arrest and apoptosis in human renal carcinoma cell lines.
Yang FG; Zhang ZW; Xin DQ; Shi CJ; Wu JP; Guo YL; Guan YF
Acta Pharmacol Sin; 2005 Jun; 26(6):753-61. PubMed ID: 15916743
[TBL] [Abstract][Full Text] [Related]
8. Regulation of the growth arrest and DNA damage-inducible gene 45 (GADD45) by peroxisome proliferator-activated receptor gamma in vascular smooth muscle cells.
Bruemmer D; Yin F; Liu J; Berger JP; Sakai T; Blaschke F; Fleck E; Van Herle AJ; Forman BM; Law RE
Circ Res; 2003 Aug; 93(4):e38-47. PubMed ID: 12881480
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of human lung cancer cell growth by the peroxisome proliferator-activated receptor-gamma agonists through induction of apoptosis.
Tsubouchi Y; Sano H; Kawahito Y; Mukai S; Yamada R; Kohno M; Inoue K; Hla T; Kondo M
Biochem Biophys Res Commun; 2000 Apr; 270(2):400-5. PubMed ID: 10753637
[TBL] [Abstract][Full Text] [Related]
10. Troglitazone induces G1 arrest by p27(Kip1) induction that is mediated by inhibition of proteasome in human gastric cancer cells.
Takeuchi S; Okumura T; Motomura W; Nagamine M; Takahashi N; Kohgo Y
Jpn J Cancer Res; 2002 Jul; 93(7):774-82. PubMed ID: 12149143
[TBL] [Abstract][Full Text] [Related]
11. Troglitazone inhibits tumor growth in hepatocellular carcinoma in vitro and in vivo.
Yu J; Qiao L; Zimmermann L; Ebert MP; Zhang H; Lin W; Röcken C; Malfertheiner P; Farrell GC
Hepatology; 2006 Jan; 43(1):134-43. PubMed ID: 16374840
[TBL] [Abstract][Full Text] [Related]
12. Induction of G1 phase arrest and apoptosis in MDA-MB-231 breast cancer cells by troglitazone, a synthetic peroxisome proliferator-activated receptor gamma (PPARgamma) ligand.
Yu HN; Lee YR; Noh EM; Lee KS; Kim JS; Song EK; Han MK; Lee YC; Kwon KB; Lee SJ; Youn HJ; Jung SH
Cell Biol Int; 2008 Aug; 32(8):906-12. PubMed ID: 18474441
[TBL] [Abstract][Full Text] [Related]
13. Troglitazone inhibits growth of MCF-7 breast carcinoma cells by targeting G1 cell cycle regulators.
Yin F; Wakino S; Liu Z; Kim S; Hsueh WA; Collins AR; Van Herle AJ; Law RE
Biochem Biophys Res Commun; 2001 Sep; 286(5):916-22. PubMed ID: 11527386
[TBL] [Abstract][Full Text] [Related]
14. PPAR gamma ligand-induced apoptosis through a p53-dependent mechanism in human gastric cancer cells.
Nagamine M; Okumura T; Tanno S; Sawamukai M; Motomura W; Takahashi N; Kohgo Y
Cancer Sci; 2003 Apr; 94(4):338-43. PubMed ID: 12824901
[TBL] [Abstract][Full Text] [Related]
15. The effect of peroxisome proliferator-activated receptor-gamma ligand on urological cancer cells.
Yoshimura R; Matsuyama M; Hase T; Tsuchida K; Kuratsukuri K; Kawahito Y; Sano H; Segawa Y; Nakatani T
Int J Mol Med; 2003 Dec; 12(6):861-5. PubMed ID: 14612958
[TBL] [Abstract][Full Text] [Related]
16. PPARgamma inhibits the expression of c-MET in human gastric cancer cells through the suppression of Ets.
Kitamura S; Miyazaki Y; Hiraoka S; Toyota M; Nagasawa Y; Kondo S; Kiyohara T; Shinomura Y; Matsuzawa Y
Biochem Biophys Res Commun; 1999 Nov; 265(2):453-6. PubMed ID: 10558888
[TBL] [Abstract][Full Text] [Related]
17. Peroxisome proliferator-activated receptor gamma ligands suppress colon carcinogenesis induced by azoxymethane in mice.
Osawa E; Nakajima A; Wada K; Ishimine S; Fujisawa N; Kawamori T; Matsuhashi N; Kadowaki T; Ochiai M; Sekihara H; Nakagama H
Gastroenterology; 2003 Feb; 124(2):361-7. PubMed ID: 12557142
[TBL] [Abstract][Full Text] [Related]
18. Expression of peroxisome proliferator-activated receptor (PPAR)gamma in gastric cancer and inhibitory effects of PPARgamma agonists.
Sato H; Ishihara S; Kawashima K; Moriyama N; Suetsugu H; Kazumori H; Okuyama T; Rumi MA; Fukuda R; Nagasue N; Kinoshita Y
Br J Cancer; 2000 Nov; 83(10):1394-400. PubMed ID: 11044367
[TBL] [Abstract][Full Text] [Related]
19. Ligands for peroxisome proliferator-activated receptor gamma inhibit growth and induce apoptosis of human papillary thyroid carcinoma cells.
Ohta K; Endo T; Haraguchi K; Hershman JM; Onaya T
J Clin Endocrinol Metab; 2001 May; 86(5):2170-7. PubMed ID: 11344222
[TBL] [Abstract][Full Text] [Related]
20. PPARgamma ligands inhibit cholangiocarcinoma cell growth through p53-dependent GADD45 and p21 pathway.
Han C; Demetris AJ; Michalopoulos GK; Zhan Q; Shelhamer JH; Wu T
Hepatology; 2003 Jul; 38(1):167-77. PubMed ID: 12829999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
